Pegfilgrastim

Evidence Level: L5

Predicted Indications: 2

Pegfilgrastim

Pharmacist Assessment Report

Pegfilgrastim: From Neutropenia Prevention to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Pegfilgrastim is a long-acting form of granulocyte colony-stimulating factor (G-CSF), a protein that stimulates neutrophil production. The TxGNN model predicts it may be relevant for severe nonproliferative diabetic retinopathy, but there are currently 0 clinical trials and 0 publications supporting this direction. This is a model prediction only.

Quick Overview

Item	Content
Original Indication	Not stated in the data compiled for this report (the ARTG entry has no indication text)
Predicted New Indication	Severe nonproliferative diabetic retinopathy
TxGNN Prediction Score	0.9989
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Pegfilgrastim is a G-CSF analogue that stimulates neutrophil production. Its established use is in supporting neutrophil recovery, but the approved indication text was not included in the data compiled for this report.

The link to diabetic retinopathy is speculative. One hypothesis is that G-CSF mobilises haematopoietic or endothelial progenitor cells, which might influence retinal microvascular repair. No data support this. Neutrophil-mediated inflammation could also worsen retinal damage, so the direction of any effect is uncertain. The high score (0.9989) is a model output and should not be read as evidence of efficacy.

Other predicted indications were also reviewed, and none has supporting trials or literature:

Predicted Indication	TxGNN Score	Evidence Level	Comment
Diabetic retinopathy	0.9973	L5	Overlaps with the lead prediction; no supporting evidence

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 6363X	Ziextenzo	Injection 6 mg in 0.6 mL single use pre-filled syringe	Not stated in the data compiled for this report

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Drug Interactions: The interaction screen returned 100 entries. The 20 reviewed here were all rated Moderate. They include:

Cytotoxic and antineoplastic agents: paclitaxel, mercaptopurine, azacitidine, arsenic trioxide, altretamine, trimetrexate and asparaginase (E. coli)
Targeted and biologic agents: abemaciclib, acalabrutinib, avapritinib, alemtuzumab, aldesleukin and belantamab mafodotin
Radiopharmaceuticals and radioimmunotherapy: iobenguane (I-131), tositumomab (with and without I-131), ibritumomab tiuxetan and fludeoxyglucose (18F)
Others: levamisole and pegvaliase

The remaining 80 interactions were not itemised in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on model output alone, with no registered trials, no publications and no supported mechanism. Pegfilgrastim has no demonstrated benefit in diabetic retinopathy, and inflammatory effects could plausibly be harmful in the retina.

To proceed, the following is needed:

Mechanism of action data and a plausible biological rationale for retinal disease
A systematic literature search, including preclinical studies of G-CSF in diabetic retinopathy models
The TGA Product Information, including approved indications, warnings and contraindications
Review of the full interaction list and of ocular safety signals
Preclinical evidence of benefit before any clinical trial is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.